Applications for the LMB PhD programme are now open. Deadline 3rd December 2024.
About Us
The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, we provide knowledge needed to solve key problems in human health.
Our scientists tackle fundamental, often difficult and long-term research problems. The LMB has made revolutionary contributions to science, such as pioneering X-ray crystallography and electron cryo-microscopy (cryo-EM) to determine protein structures, the sequencing of DNA and the development of monoclonal antibodies. Twelve Nobel Prizes have been awarded for work carried out by LMB scientists.
The LMB also promotes the application and exploitation of our research findings, both by collaboration with existing companies and the founding of new ones, helping to advance medical research and the translation and application of knowledge.
The LMB provides an unsurpassed environment for both young and established researchers, with state-of-the-art facilities and a unique scientific culture. The LMB has always been very diverse, with a truly international outlook. We currently employ men and women from over 50 countries, and LMB alumni work in research organisations across the world.
Insight on Research
New potential therapy for neurodegeneration removes tau aggregates and improves motor function
Leo James’ group, in the LMB’s PNAC Division, have worked with Will McEwan’s group at the UK Dementia Research Institute to design two new therapeutics which harnesses cellular machinery to remove tau aggregates, improving motor skills in mice affected by neurodegenerative disease.
Unprecedented heteromeric amyloid structure in neurodegenerative disease
Surprising advance to our understanding of neurodegenerative diseases, as Diana Arseni and Benjamin Ryskeldi-Falcon in the LMB’s Neurobiology Division find that frontotemporal lobar degeneration Type C filaments include both annexin A11 and TDP-43 in a unique heteromeric structure.
Quick Links
Latest News
- The LMB welcomes new Group Leader Joergen Kornfeld
Joergen Kornfeld’s group in the LMB’s Neurobiology Division will investigate the connectomics of learned behaviour using the zebra finch as a model. […]
- Diana Arseni appointed Group Leader in the LMB’s Neurobiology Division
Diana Arseni’s research group in the LMB’s Neurobiology Division will study mechanisms of brain health, ageing and disease focusing on the lysosomal protein TMEM106B. […]
Latest Publications
- HIV-1 adapts to lost IP6 coordination through second-site mutations that restore conical capsid assembly.
Kleinpeter, A., Mallery, DL., Renner, N., Albecka, A., Klarhof, JO., Freed, EO., James, LC.
Nat Commun 15(1): 8017. (13th September 2024) - Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesis.
Pacyna, CN., et al.
Oncogene [Epub ahead of print]. (13th September 2024) - Prebiotic chiral transfer from self-aminoacylating ribozymes may favor either handedness.
Kenchel, J., et al.
Nat Commun 15(1): 7980. (12th September 2024) - A brain-to-gut signal controls intestinal fat absorption.
Lyu, Q., et al.
Nature [Epub ahead of print]. (11th September 2024) - Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP Type C.
Arseni, D., et al.
Nature [Epub ahead of print]. (11th September 2024) - Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function.
Miller, LVC., et al.
Cell [Epub ahead of print]. (10th September 2024) - A Fragment-Based Competitive F LB-NMR Platform For Hotspot-Directed Ligand Profiling.
McCarthy, WJ., et al.
Angew Chem Int Ed Engl 63(37): e202406846. (9th September 2024)
See more Publications